precisionbiosciences.com (DTIL) - Debt to Equity

Precision BioSciences enjoys global recognition due to its innovative ARCUS gene editing system. A team of leading biologists is developing breakthrough treatments, supported by generous research investments and competitive compensation. This chart of the asset's market value on GURU.Markets demonstrates a debt-to-equity ratio of 0.58. Its status as a niche leader and alliances with industry behemoths guarantee the brand an impeccable reputation.

The development of the ARCUS platform requires significant capital expenditures; therefore, this calculation determines the ratio of debt to equity to assess the financial autonomy of Precision BioSciences (DTIL). By analyzing the company's leverage history, an investor can understand the business's degree of dependence on creditors, which is critical for confirming the asset's stability during the scaling of genome editing technologies.